Anika Therapeutics, Inc.ANIKNASDAQ
Loading
ANIK Revenue Growth (YoY Quarterly)•+0.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.00%
+28.2pp
-15.01%
-997.2pp
-91.71%
-91.7pp
-97.68%
-97.7pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
-2.09%
+0.7pp
-0.35%
+2.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -103.00% | -35.42% | -8.15% | -28.22% | +0.00% |
| Gross Profit Growth | -14.30% | -40.39% | -29.90% | +982.22% | -15.01% |
| EBITDA Growth | +1237.82% | +0.00% | -1214.52% | +0.00% | -91.71% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -97.68% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -0.48% | -2.73% | -3.42% | -2.76% | -2.09% |
| Weighted Average Shares Diluted Growth | +0.51% | -2.73% | -3.42% | -2.76% | -0.35% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -56.51% | +0.00% | +0.00% | +36.96% | +193.11% |
| Free Cash Flow Growth | -84.71% | +0.00% | +0.00% | +55.72% | +1350.55% |
| Receivables Growth | -10.49% | -31.46% | -29.07% | -21.76% | +0.41% |
| Inventory Growth | -2.53% | -56.82% | -67.12% | -58.91% | -21.09% |
| Asset Growth | -25.09% | -27.73% | -28.54% | -18.14% | -6.15% |
| Book Value per Share Growth | -27.11% | -26.84% | -27.30% | -16.07% | -4.85% |
| Debt Growth | -6.52% | -10.66% | -11.00% | -10.99% | -6.69% |
| R&D Expense Growth | -63.90% | -25.78% | -5.52% | -4.11% | +135.65% |
| SG&A Expenses Growth | -124.05% | -40.05% | -21.69% | -37.89% | +0.00% |
1 / 4